

Learner Notification

MED Learning Group

Guideline-Driven Care to Reduce Exacerbations in Moderate-to-Severe Asthma

June 12, 2023 – June 12, 2024

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc., Sanofi

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Translate evidence-based guidelines into clinical strategies for prompt diagnosis and treatment selection to reduce the occurrence of exacerbations.
2. Discuss individualized treatment plans that include communication and shared decision-making strategies for patients with asthma.
3. Describe the clinical data for recently approved and investigational agents for the treatment of moderate to severe asthma.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Diego J.	Maselli	Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Sanofi Regeneron: Consultant, AstraZeneca, GlaxoSmithKline, Sanofi Regeneron: Speakers Bureau
Njira	Lugogo	AstraZeneca, Avillion, Sanofi.Regeneron, Teva, Genentech, GSK: Consultant, GSK: Speakers Bureau, AstraZeneca, Amgen, Sanofi, Regeneron, Teva, GSK, Avillion, Genentech: Contracted Research
Matthew	Frese	NA
Christina	Gallo	NA
Tara	Mayfield	NA
Felecia	Beachum	NA
Naomi	De Brito	NA
Lauren	Welch	NA
Aimee	Meissner	NA

Jo

Shultz

NA

Questions? Email Certificate@AmedcoEmail.com